Various factors, including drugs as well as non-molecular influences, induce alterations in the stability of proteins in cell lysates, living cells and organisms. These alterations can be probed by applying a stability-modifying agent, such as elevated temperature, to a varying degree. As a second dimension of variation, drug concentration or factor intensity can be used. However, the corresponding analysis scheme has a low throughput and high cost. Additionally, since traditional data analysis employs curve fitting, proteins with unusual behavior are frequently ignored. The novel Proteome Integral Stability Alteration (PISA) assay avoids these issues altogether, increasing the analysis throughput by one to two orders of magnitude for unlimited number of parameter variation points. The consumption of the compound and biological material decreases by the same factor. We envision widespread use of the PISA approach in chemical biology and drug development. 
Introduction
Various internal and external factors, including drugs, nutrients and metabolites, as well as non-molecular influences, such as radiation, etc., induce alterations in the stability of proteins in cell lysates, living cells and organisms. These alterations can be probed on the proteome-wide scale by applying a stability-modifying agent, such as elevated temperature (Savitski et al., 2014) , proteolytic enzyme (Lomenik et al., 2009; Piazza et al., 2018) , chaotropic agent, such as urea (Park and Maqusee, 2005) , or salt (Vedadi et al., 2006) . The agent is typically applied to a varying degree in a step-wise manner, and the fraction of the proteome remaining stable or, alternatively, the fraction becoming unstable, is analyzed. The protein stability can be assessed by, e.g., measuring the fraction of molecules remaining soluble at given conditions. The obtained information can be interpreted as drug binding to protein targets (Becher at al., 2016; Dart et al., 2018) , as well as protein-protein docking, protein-small molecule interactions, or post-translational modifications Becher et al., 2018; Dai et al., 2018; Saei et al., 2018) .
One such popular method of monitoring the changes in protein stability is thermal proteome profiling (TPP) (Savitski et al., 2014) , that has translated onto a proteomewide scale the targeted approach of cellular thermal shift assay, CETSA (Molina et al., 2013) , which, in turn, is based on a well known concept of protein melting temperature shift, widely used in drug discovery and development. Changes in protein's physicochemical properties due to temperature variations have previously been applied to test interactions of this protein with other molecules using as a read-out fluorescence (Lo et al., 2004; Nielsen et al., 2007) , calorimetry (Bruylants et al., 2005) , differential scanning calorimetry (Brandts & Lin, 1990) or mass spectrometry (West et al., 2012) . For instance, Garbett et al. (Garbett et al., 2009 ) have used differential scanning calorimetry of the unfractionated plasma, attributing changes in signature thermograms not to changes in the protein concentrations, but to interactions of these proteins with small molecules and peptides.
TPP is not restricted to the detection of protein-compound interactions (e.g., Park et al., 2017; Massey, 2018; Miettinen et al., 2018; Türkowsky et al., 2018) , but has ≤ 5000 proteins. In order to increase the depth of the proteomics analysis to 5000-10,000 proteins, the mixture is Often, such a 1D TPP analysis does not provide sufficient specificity to uniquely identify the protein most affected by the factor or even confine it to a short list of 3-5 most probable candidates. For specificity increase, a second dimension of analysis can be added, where the drug concentration (or factor intensity) is varied from zero to some maximum value (usually, 5-10 times higher than the IC 50 ), while the temperature is fixed (Savitski et al., 2014) . A sigmoid curve fitting can also be performed in the concentration domain, similar to the temperature domain (Figure 1b ). The measured parameter in the second dimension is the concentration C 0 (or pEC50, as in Savitski et al., 2014) at which the drug induces in a given protein thermal shift amounting to half of the per experiment is a challenge for any cell culture facility, since all cells need to be in a nearly identical biological state, as even small changes in the environment during cell growth can significantly affect the abundances of cellular proteins .
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The curve fitting procedure to obtain Tm values presents another challenge.
Some proteins increase (or appear to increase) their solubility with temperature, as do most molecules, and only upon reaching a significantly elevated temperature their structure starts to unfold, which finally results in solubility drop. The melting curves of such proteins can exhibit bumps, bimodal behavior or other unexpected features that can result in a low fitting score . Indeed, although the melting of proteins is usually considered to be a two-state transition from a defined folded native structure to a random coil, intermediate structures are often present (Biltonen & Freire, 1978; El-Baba et al., 2017) . Moreover, some proteins, e.g. ribosomal units, are engaged in strong noncovalent complexes that fall apart only at significantly elevated temperatures. A sigmoidal curve fails to fit properly the melting behavior of many such proteins. Recently introduced non-parametric analysis of TPP data is more robust against deviations from the expected sigmoid shape (Childs et al., 2018) , but it alleviates the problem of poor fitting only partially. As a result, problematic proteins are usually discarded from the final protein list, which increases the risk of false negative identifications (misses).
In order to solve or drastically reduce the impact of the above problems on the analysis results, we developed the Proteome Integral Stability Alteration (PISA) assay which achieves dramatic reduction in both analysis time and sample consumption by taking the following steps:
1. In a 1D PISA assay, two protein samples per replicate are analysed, one with the factor (drug) applied and another one -without the factor.
For each of these two samples, the protein mixtures corresponding to 
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The standard TMT-10 labeling set can multiplex three 2D PISA replicates, with one TMT channel remaining vacant. This vacancy can be filled by an untreated proteome, which can be used for normalizing the S m values (Figure 1h ). According to our simulations, such a normalization can somewhat improve the precision. Alternatively, the vacancy can be filled by an untreated proteome obtained using detergent for enhanced protein extraction. Conventional TPP protocols tend to avoid detergents, as they affect protein solubility Seashore-Ludlow & Lundbäck, 2016) . This avoidance results in underrepresentation of less soluble proteins in TPP; inclusion of the detergent-assisted untreated proteome may cure this deficiency. The untreated proteome will play here the role similar to the carrier proteome in the single-cell proteomics approach introduced by Budnik et al. (Budnik et al., 2018) . 
Simulations

Ab initio simulation of 2D PISA
As a theoretical proof of principle, we simulated in Excel the melting curves of 1000 proteins, with the melting temperatures Tm chosen randomly in the range from 42 °C to 57 o C. N t =16 temperature points between 37 °C and 67 °C with a 2 °C step were chosen. Sigmoidal melting curves were simulated by calculating the relative intensity I(T) for a given temperature T as:
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where ERF is the error function, and SQRT -the square root function. Examples of thus simulated melting curves are given in Figure 2a .
The measured signal Sm was calculated as the sum of I(T) values for all temperature points. When the proteins were ranked by Tm and, separately, by Sm, the ranks were found to be exactly the same, validating the hypothesis that Sm is a suitable proxy for Tm.
The drug-induced melting temperature shifts 
where C is a given concentration point, and ^ is the power function. Examples of the response function for two different C 0 values are given in Figure 2c .
The measured read-out Sm" is simulated as Sm" = SUM(Sm + R(C)*(Sm' -Sm)). The reduced parameter Sm"* is extracted from the measured values as
where n is the number of concentration points used. Again, the protein rank by Sm"* turned out to coincide with the rank by C 0 , confirming that the former parameter is a suitable proxy of the latter. An excellent linear correlation (R 2 > 0.998) was found between Sm"* and -log10(C 0 ) (Figure 2d ). Thus, using linear regression, one can extract the model C 0 values from S"* data. 
Simulation of 1D PISA output from experimental TPP results
Another proof of principle for the PISA approach was derived from the conventional TPP data, in which the abundances corresponding to different temperature points were added together to simulate the PISA read-out. 
Experimental
1D PISA assays on MTX and 5-FU
For purely experimental proof of principle, the PISA assay was performed on cells using two cell lines (lung carcinoma A549 and kidney carcinoma A498) and two drugs with well-known targets. In particular, we used the folate and nucleoside analogs methotrexate MTX and 5-fluorouracil (5-FU), known to inhibit, respectively, DHFR, an enzyme involved in the tetrahydrofolate synthesis, and TYMS, a key enzyme in de novo synthesis of thymidylate (Vincente et al., 2013; Qiu et al., 2017; Rajagopalan et al., 2002; Visentin et al. 2012; Wyatt et al. 2009 ). These drugs and their targets have already been subjects of CETSA investigations using antibody-based targeted protein detection, with the targets showing an increased stability after drug incubation Almqwist et al., 2016) . The identification of DHFR and TYMS as targets of MTX and 5-FU, respectively, was also performed by Functional identification by expression proteomics (FITExP) (Chernobrovkin et al., 2014) , a proteome-wide MSbased proteomics method for drug target deconvolution which is orthogonal to thermal shift approaches. Figure 1h . For treatment, we used a drug concentration corresponding to 5-10 times the IC 50 value, and vehicle (solution without the drug) as a control. All experiments on both cells and lysates were performed in 5 biological replicates. The lysates were treated at N t =15 temperature points for 3 min each, and then pooled together after allowing precipitation at room temperature for 6 min and before centrifugation and digestion. Following TMT10 labeling of the digests, the samples were pooled and separated into 24 fractions by high pH reverse phase chromatography. The LC-MS/MS analysis was performed on 1 5
an Orbitrap Q Exactive HF system. Protein identification and relative quantification was performed by as conventional in shotgun proteomics.
For MTX in A549 cells (Figure 4a ), both DHFR and TYMS were clearly determined as by far the biggest positive outliers in the ∆ Sm distribution. In lysate, only DHFR was an outlier (Figure 4b ), while ∆ Sm value for TYMS was very small. This result confirmed DHFR to be the primary target of MTX and TYMS to be a secondary target that binds a metabolized form of MTX (Qiu et al., 2017) . Similar results were obtained for 5-FU that also binds to TYMS after metabolic modification (Longley et al., 2003): while in A498 cells TYMS is a clear positive outlier (Figure 4c) , in a lysate the ΔSm value for TYMS was not significant (Figure 4d ). 
1D PISA assay on 9 drugs
To demonstrate the unique analytical power of PISA arising from great reduction of the sample number, we treated A549 cell lysate with 9 drugs (Nutlin, Tomudex, Floxuridine, Topotecan, Bortezomib, Dasatinib, Gefitinib, and Vincristine) at 10 µM for 45 min as well as vehicle. These 9 drugs have previously been used in deep-proteome FITExP analysis . Then we performed PISA analysis, multiplexing the 9 drugs and control into a TMT-10 sample in a biological triplicate, separating each replicate into 24 fractions and analyzing them by LC-MS/MS. The 72 analyses took less than a week of instrumental time, while with TPP the same effort would require two and a half month, a prohibitively expensive enterprise for most research groups. The analysis yielded 7200 proteins quantified in all replicates, and allowed us to apply the specificity concept previously used only in FITExP and SIESTA -namely, contrasting, for every protein, the ∆ Sm value for any particular drug to those for all other drugs. This was done by the OPLS-DA method. As an example, Dasatinib that targets kinases showed many kinases specifically stabilized or destabilized. To increase the analysis specificity, Gefitinib that has similar targets was removed from the dataset (Figure 5a ).
For the first time, it became possible to compare the data on specific expression (FITExP) with those on specific thermal shift (PISA) on 5600 common proteins and prove the orthogonality of these two methods. As an example, the Floxuridine target TYMS shows elevated expression as well as positive stabilisation; it is an outlier in both types of analysis when Tomudex that has the same target is removed (Figure 5b ). 
Discussion
Specificity increase
The specificity increase in PISA compared to TPP can come from three sources. First, it is the possible use of a larger number of temperature points N t , as this incurs no additional cost in terms of LC-MS/MS instrumental time. Larger N t with the same temperature range means smaller errors associated with the discrete character of measurements, and more accurate capturing of the behavior of proteins with steep melting curves. The use of more temperature points will also mitigate the error arising due to statistical noise, e.g., single point outliers. The only limitation on N t is practical.
We tested N t =20 temperature points and received lower p-values for known target proteins than with N t =10. Note that, for increased dynamic range of the readout, the temperature range can be narrowed to the region of the most significant solubility changes, excluding both the lowest and the highest temperatures where the difference between the treated and untreated samples is small. The third reason is the larger number of replicates that can be analyzed in practice. We mentioned above that a standard TMT-10 labeling scheme allows for simultaneous analysis of five replicates of both treated and untreated samples, while in published TPP studies we found no more than three replicates. The much larger statistical power of the five-replicate experiment allows one to identify with high significance even proteins with tiny thermal shift.
Throughput increase
With the same number of replicates, 1D PISA analysis provides a throughput increase by a factor of N t compared to TPP, while 2D PISA gives an increase of N t ·N c . With both N t and N c being of the order of 10, the throughput increase in 2D PISA can reach two orders of magnitude.
Sensitivity increase
One of the limiting factors in TPP is the minimum volume (usually, ≈ 10 µL) of lysate allowing for reliable supernatant collection after ultracentrifugation of the thermally treated sample. In 1D PISA, where the samples are merged before centrifugation, reduction of the minimal volume per sample is by a factor of N t . Similarly, in 2D PISA, where the samples for different drug concentrations are merged before thermal treatment, the overall reduction of sample volume is N t ·N c times.
Cost reduction
The costs of a PISA experiment arises from the use of biological materials, chemicals (e.g., TMT10 labeling reagents), labor for sample treatment and preparation for the LC-MS/MS analysis, as well as the LC-MS/MS analysis itself. The reduction in the volume of biological material (mainly, cells) is similar to the above increase in sensitivity. In drug discovery, the cost of an experimental drug can be quite substantial, and thus the cost reduction in PISA can be high. Besides, in our recent TPP-based method of SIESTA , where a recombinant enzyme is added to a cell lysate together with a co-factor, the cost of a recombinantly produced and purified enzyme with validated activity can exceed the cost of the LC-MS/MS part of SIESTA, scaling up with the required enzyme amount. Therefore, SIESTA is one of the analysis types that will greatly benefit from the use of PISA instead of TPP. Additional cost reduction comes from the TMT reagents and LC-MS/MS instrumental time, which are usually the most expensive items in TPP. Paradoxically, labor and chemicals become the dominant cost items in PISA while the LC-MS/MS instrumental time becomes a lesser component.
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Applicability area
The main idea behind PISA -the use of the integral under the curve instead of the curve shape parameters -can be applied in many analytical methods were curve fitting is employed to probe protein stability or solubility, e.g. in limited proteolysis combined with MS (Leuenberger et al., 2017) , in the use of urea or other chaotropic agents, pressure or high (low) pH values, or high (low) salt concentrations.
